Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EVEX vs SRTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRTA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

SRTA Overall Winner 6-Pillar Tally: EVEX 1 – 5 SRTA Matrix Metrics: EVEX 4 – 6 SRTA

As of Nov 16, 2026, Strata Critical Medical, Inc. (SRTA) is the stronger overall head-to-head candidate over Eve Holding, Inc. (EVEX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). EVEX carries a Unified Composite Score of 41.3/100 (SELL) at $1.70 (N/M Forward P/E, 0.0% operating margin), whereas SRTA carries 29.9/100 (SELL) at $5.38 (71.1x Forward P/E, -4.7% operating margin).

  • Composite vs. Pillar Nuance: While EVEX currently prints a higher short-term Unified Composite Score (41.3/100 SELL vs. SRTA 29.9/100 SELL), SRTA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-4.7% vs. 0.0% operating margin) and revenue trajectory (+50.3% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although SRTA compares more favorably head-to-head, both EVEX (41.3/100 SELL) and SRTA (29.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: EVEX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8); meanwhile SRTA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EVEX vs SRTA
EVEX NYSE
Eve Holding, Inc.
Aircraft
$1.70
+2.41% 1D
Market Cap $597.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.71β · 96% Vol
Unified Composite Score
41.3 / 100 SELL
Tech 20.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.6%), weak momentum, RSI 43
RSI-14: 42.8 · SMA20: $1.68 · SMA50: $1.81
SRTA NASDAQ Head-to-Head Winner
Strata Critical Medical, Inc. Class A Common Stock
Air Transportation, Nonscheduled
$5.38
-2.45% 1D
Market Cap $515.4M
TTM Revenue $281M
Forward P/E 71.1x
Beta / 30D Vol 1.97β · 82% Vol
Unified Composite Score
29.9 / 100 SELL
Tech 50.0 Fund 31.0 Flow 57.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.5 · SMA20: $5.09 · SMA50: $5.02

6-Pillar Scorecard Institutional Category Breakdown (EVEX 1 – 5 SRTA)

Columns: Metric · EVEX · SRTA
1. Valuation Multiples SRTA
Forward P/E N/M 71.1x
Trailing P/E N/M 138.9x
PEG Ratio N/M N/M
EV / Revenue N/M 1.7x
2. Growth & Scale SRTA
Revenue Growth (YoY) +0.0% +50.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $281M
Market Cap $597.7M $515.4M
3. Profitability & Quality EVEX
Gross Margin N/A 21.6%
Operating Margin 0.0% -4.7%
Net Profit Margin 0.0% -8.8%
Return on Equity (ROE) -300.9% -7.5%
4. Balance Sheet & Cash Flow SRTA
Cash Generation (TTM) N/A -$382,000
Cash Flow Margin N/A -0.1%
Net Cash / Leverage -300.9% ROE $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRTA
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 72.3% (50th %ile) 61.9% (8th %ile)
Put/Call OI Skew N/A 0.43x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SRTA
OpEx & R&D Intensity N/A 26.3% of Rev ($74M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Aerospace & Defense Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EVEX (4) vs SRTA (6)
Institutional Metric EVEX SRTA Criterion Row Edge
Market Capitalization
Scale
$597.7M $515.4M Larger Scale EVEX
Trailing P/E Ratio
Valuation
N/M 138.9x Lower Multiple SRTA
Forward P/E Ratio
Valuation
N/M 71.1x Lower Multiple SRTA
Revenue Growth (YoY)
Growth
+0.0% +50.3% Higher Growth SRTA
Operating Margin (TTM)
Profitability
0.0% -4.7% Higher Margin EVEX
Net Profit Margin
Profitability
0.0% -8.8% Higher Margin EVEX
Return on Equity (ROE)
Capital Efficiency
-300.9% -7.5% Higher ROE SRTA
52-Week Range Position
Momentum
8% ($1–$5) 56% ($4–$6) Stronger Trend SRTA
Beta / 30D Volatility
Risk Regime
2.71β · 96% Vol 1.97β · 82% Vol Lower Realized Risk SRTA
Unified Institutional Score
Composite Signal
41.3 / 100 (SELL) 29.9 / 100 (SELL) Higher Composite EVEX
Trailing 12M Revenue (USD)
Operating Scale
N/A $281M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 21.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (-300.9% ROE) -$382,000 ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRTA +13.45 pp
EVEX: +4.94% · SRTA: +18.39%
3M Horizon SRTA +30.15 pp
EVEX: -35.85% · SRTA: -5.7%
6M Horizon SRTA +41.06 pp
EVEX: -40.97% · SRTA: +0.09%
1Y Horizon SRTA +69.05 pp
EVEX: -59.13% · SRTA: +9.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVEX vs SRTA. Trailing 12-month operating profitability (EVEX 0.0% vs SRTA -4.7%) and valuation multiples (EVEX N/M vs SRTA 71.1x Forward P/E) are benchmarked directly in Pillar 4 below.

EVEX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-300.9% · N/M
SRTA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$281M
Gross Margin21.6%
Op. Margin-4.7%
ROE / Fwd P/E-7.5% · 71.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EVEX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 72.3%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EVEX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SRTA CONSOLIDATION
119d in phase · OBV NEUTRAL
Current IV 61.9%
IV Percentile 8th %ile
Put/Call OI Skew 0.43x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EVEX Moat Profile Cyclical / Execution-Driven Positioning
Aerospace & Defense Operator
Competes within the Aerospace & Defense value chain with $597.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SRTA Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $515.4M market capitalization and -4.7% operating margin.
OpEx & R&D Reinvestment 26.3% of Rev ($74M)
90D Engineering Disclosures 0 Published

Investor FAQ EVEX vs SRTA Key Questions & Quantitative Answers

As of Nov 16, 2026, Strata Critical Medical, Inc. (SRTA) is the stronger overall head-to-head candidate over Eve Holding, Inc. (EVEX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). EVEX carries a Unified Composite Score of 41.3/100 (SELL) at $1.70 (N/M Forward P/E, 0.0% operating margin), whereas SRTA carries 29.9/100 (SELL) at $5.38 (71.1x Forward P/E, -4.7% operating margin). Composite vs. Pillar Nuance: While EVEX currently prints a higher short-term Unified Composite Score (41.3/100 SELL vs. SRTA 29.9/100 SELL), SRTA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-4.7% vs. 0.0% operating margin) and revenue trajectory (+50.3% vs. +0.0% YoY). Defensive Composite Rating Caution: Although SRTA compares more favorably head-to-head, both EVEX (41.3/100 SELL) and SRTA (29.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: EVEX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8); meanwhile SRTA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRTA leads the Growth & Scale pillar: EVEX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SRTA at +50.3% YoY revenue growth and +0.0% YoY earnings growth on $281M TTM revenue (21.6% gross margin, -4.7% operating margin). On trailing 12-month operating scale, EVEX generates N/A in USD-normalized revenue versus $281M for SRTA. In operating R&D and SG&A reinvestment, EVEX deploys N/A (0 90-day corporate R&D disclosures) versus 26.3% of Rev ($74M) (0 disclosures) for SRTA.

SRTA screens cheaper on headline valuation multiples. EVEX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SRTA trades at 71.1x Forward P/E, 138.9x Trailing P/E, N/M PEG, and 1.7x EV/Revenue (-0.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVEX (-300.9% ROE) versus SRTA (-7.5% ROE) capital efficiency.

In options market volatility and institutional positioning, EVEX carries 72.3% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.71β · 96% Vol realized risk). By comparison, SRTA carries 61.9% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.43x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.97β · 82% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.